Lung Cancers Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: LUng Cancer / Cancer, Lung / Lung neoplasm malignant / Lung cancer NOS / Cancer of lung / Ca lung

IndicationStatusPhase
DBCOND0072929 (Lung Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00563784TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT01116219Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).Treatment
NCT01562028BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)Treatment
NCT00100854Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00287989Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung CancerTreatment
NCT00547105Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerTreatment
NCT00411632BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Treatment
NCT00661193S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00553462Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryTreatment
NCT00445848S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung CancerTreatment
NCT01344824Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never SmokersTreatment
NCT02625168Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLCTreatment
NCT00660816Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT00585533A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung CancerTreatment
NCT00673569Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous TreatmentTreatment
NCT00367601Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung CancerTreatment
NCT00370383A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)Treatment
NCT00410059BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLCTreatment
NCT00416650Erlotinib in Treating Patients With Advanced Non-Small Cell Lung CancerTreatment
NCT00283244Gemcitabine and/or Erlotinib as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTreatment
NCT01565538Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung AdenocarcinomaTreatment